Retrieve available abstracts of 17 articles: HTML format
Single Articles
May 2025
WANG Y, Ohnuki H, Tran AD, Wang D, et al Induced clustering of SHP2-depleted tumor cells in vascular islands restores
sensitivity to MEK/ERK inhibition.
J Clin Invest. 2025;135:e181609. PubMedAbstract available
TORRES ACOSTA MA, Gurkan JK, Liu Q, Mambetsariev N, et al AMPK is necessary for Treg functional adaptation to microenvironmental stress
during malignancy and viral pneumonia.
J Clin Invest. 2025;135:e179572. PubMedAbstract available
HYUN H, Sun B, Yazdimamaghani M, Wielgus A, et al Tumor-specific surface marker-independent targeting of tumors through
nanotechnology and bioorthogonal glycochemistry.
J Clin Invest. 2025;135:e184964. PubMedAbstract available
April 2025
STAEGER R, Tastanova A, Ghosh A, Winkelbeiner N, et al Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic
T-cells in uveal melanoma patients.
J Clin Invest. 2025 Apr 29:e181464. doi: 10.1172/JCI181464. PubMedAbstract available
January 2025
ZHANG H, Wang Z, Wu J, Zheng YQ, et al Endothelial STING-JAK1 interaction promotes tumor vasculature normalization and
antitumor immunity.
J Clin Invest. 2025;135:e180622. PubMedAbstract available
December 2024
WEN C, Wang L, Piffko A, Chen D, et al YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity
via STING-dependent type I IFN production.
J Clin Invest. 2024;134:e181612. PubMedAbstract available
October 2024
NIELSEN AJ, Albert GK, Sanchez A, Chen J, et al DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to
immunoresistant tumors.
J Clin Invest. 2024;134:e180278. PubMedAbstract available
September 2024
LI ZJ, He B, Domenichini A, Satiaputra J, et al Pericyte phenotype switching alleviates immunosuppression and sensitizes
vascularized tumors to immunotherapy in preclinical models.
J Clin Invest. 2024;134:e179860. PubMedAbstract available
VERMA S, Budhu S, Serganova I, Dong L, et al Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves
antitumor immunity in solid tumor models.
J Clin Invest. 2024;134:e177606. PubMedAbstract available
May 2024
CONWAY JR, Gillani R, Crowdis J, Reardon B, et al Somatic structural variants drive distinct modes of oncogenesis in melanoma.
J Clin Invest. 2024 May 14:e177270. doi: 10.1172/JCI177270. PubMedAbstract available
HUANG F, Goncalves C, Bartish M, Remy-Sarrazin J, et al Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and
potentiates antitumor immune responses.
J Clin Invest. 2024;134:e181575. PubMed
April 2024
ZHAN Y, Guo J, Yang W, Goncalves C, et al MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
J Clin Invest. 2024;134:e181338. PubMed
February 2024
WU M, Hanly A, Gibson F, Fisher R, et al The CoREST repressor complex mediates phenotype switching and therapy resistance
in melanoma.
J Clin Invest. 2024 Feb 1:e171063. doi: 10.1172/JCI171063. PubMedAbstract available
December 2023
KNIGHT DA, Ngiow SF, Li M, Parmenter T, et al Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
J Clin Invest. 2023;133:e177489. PubMed
November 2023
AJITH A, Mamouni K, Horuzsko DD, Musa A, et al Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived
suppressor cells and restraining anti-PD-1 resistance.
J Clin Invest. 2023;133:e167951. PubMedAbstract available
August 2023
HUANG F, Cai F, Dahabieh MS, Gunawardena K, et al Peroxisome disruption alters lipid metabolism and potentiates anti-tumor response
with MAPK-targeted therapy in melanoma.
J Clin Invest. 2023 Aug 24:e166644. doi: 10.1172/JCI166644. PubMedAbstract available
July 2023
OZBAY KURT FG, Lasser S, Arkhypov I, Utikal J, et al Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as
a therapeutic target.
J Clin Invest. 2023;133:e170762. PubMedAbstract available